BRAF Mutant Metastatic Melanoma Market: Epidemiology Analysis, Channeling Therapies, and Key Companies Working in the Market

BRAF Mutant Metastatic Melanoma Market: Epidemiology Analysis, Channeling Therapies, and Key Companies Working in the Market
BRAF Mutant Metastatic Melanoma Market: Epidemiology Analysis, Channeling Therapies, and Key Companies Working in the Market

“DelveInsight Business Research LLP”

DelveInsight’s report “BRAF-Metastatic Melanoma Market Outlook, Epidemiology and Market Forecast-2032” offers an in-depth understanding of the BRAF-Metastatic Melanoma, historical and forecast epidemiology, as well as the trends of the BRAF-Metastatic Melanoma Mutant market in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.

by DelveInsight “BRAF-Mutant Metastatic Melanoma Market Outlook, Epidemiology and Market Forecast-2032” The report offers an in-depth understanding of BRAF-mutant metastatic melanoma, historical and forecast epidemiology, as well as BRAF-mutant metastatic melanoma market trends in the US, EU5 (Germany, Spain, Italy, France, and UK), and Japan.

The BRAF Mutant Metastatic Melanoma Market Report provides current treatment practices, emerging drugs, BRAF Mutant Metastatic Melanoma market share of individual therapies, current and forecast BRAF Mutant Metastatic Melanoma market size from 2019 to 2032 segmented by seven markets main. The report also covers current BRAF Mutant Metastatic Melanoma treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to select the best opportunities and assesses the underlying potential of the BRAF Mutant Metastatic Melanoma market.

Some of the key facts of the BRAF-Mutant Metastatic Melanoma Market Report:

  • According to Cancer Research UK, melanoma is the fifth most common cancer in the UK. There are around 16,200 new cases of melanoma skin cancer in the UK each year. Melanoma skin cancer incidence rates are projected to increase by 7% in the UK between 2014 and 2035, to 32 cases per 100,000 people by 2035.

  • According to the 2020 National Organization for Rare Disorders, the incidence of this type of skin cancer is increasing at a relatively rapid rate compared to other forms of cancer. The risk of melanoma is higher in people of European descent than in other populations.

  • Darker skin pigmentation may be associated with a lower risk of metastatic melanoma. It is also associated with a higher risk for those with blue eyes and fair complexions.

Do you have questions? Click here to know more about the BRAF Mutant Metastatic Melanoma Market Landscape

Overview of BRAF Mutated Metastatic Melanoma

Melanoma is a common skin cancer that arises from melanin cells within the top layer of skin (epidermis) or from similar cells that can be found in moles (nevi). This type of skin cancer can send roots to deeper layers of the skin, and some of these microscopic roots can spread (metastasize), causing new tumor growths in vital organs of the body.

The most common driver in melanoma is mutant BRAF, which is found in 40% to 50% of patients with metastatic disease. BRAF mutations occur in other types of cancer, such as colon cancer, papillary thyroid cancer, and serous ovarian cancer, but much less frequently than in melanoma.

More serious complications include secondary infection; lymphedema; local; metastasis; and anxiety

Several unmet needs are associated with melanoma, such as the need for prognostic biomarkers, awareness, better clinical research, monitoring of immune checkpoint inhibitor toxicity, and the need for neoadjuvant therapy.

Despite the initial response seen in most patients treated with targeted therapy, acquired resistance is almost inevitable, occurring in approximately half of all patients during the first year of therapy.

Epidemiological Perspectives of the BRAF Mutant Metastatic Melanoma Market:

  • Melanoma of the skin accounts for 5.6% of all new cases of cancer in the US, with a rate of new cases of skin melanoma of 22.7 per 100,000 per year. The mortality rate was 2.3 per 100,000. These rates are age-adjusted and based on 2013-2017 cases and 2014-2018 deaths.

  • According to The Cancer Genome Atlas Network, the BRAF mutation occurs in approximately 50% of cutaneous melanomas, and the most common is V600E (valine to glutamic acid; 70–88%).

  • According to Cancer.Net, if the melanoma has spread to other distant parts of the body, the survival rate is lower, about 27%. About 4% of cases are diagnosed at this stage.

  • According to the study carried out by Jose et. a. (2020), around 42% of patients with stage IIIc and IV melanoma had BRAF mutations in Spain.

Epidemiological Segmentation of the BRAF Mutant Metastatic Melanoma Market

  • Total BRAF Metastatic Melanoma Type-Specific Cases

  • Total BRAF Metastatic Melanoma Stage-Specific Cases

  • Total cases of BRAF metastatic melanoma treated

  • Total Age-Specific Cases of BRAF Metastatic Melanoma

  • Total BRAF Metastatic Melanoma Mutation-Specific Cases

BRAF Mutant Metastatic Melanoma Market Outlook

The BRAF Mutant Metastatic Melanoma Market Outlook of the report assists in constructing a detailed understanding of the historical, current, and forecast BRAF Mutant Metastatic Melanoma market trends by analyzing the impact of current BRAF Mutant Metastatic Melanoma therapies on the market, the unmet needs. , drivers and barriers, and demand for better technology.

This segment provides comprehensive details of the BRAF-Metastatic Melanoma Mutant Market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria, mechanism of action , compliance rate, growing market need, growing patient pool, patient segment covered, expected launch year, competition with other therapies, brand value, its impact on the market, and insight from key opinion leaders. The calculated BRAF Mutant Metastatic Melanoma market data is presented with relevant Tables and Graphs to give a clear view of the market at first glance.

According to DelveInsight, the 7MM BRAF-mutant metastatic melanoma market is expected to undergo a major change in the 2019-2032 study period.

BRAF Mutant Metastatic Melanoma Key Carriers

BRAF Mutant Metastatic Melanoma Therapies

Table of Contents

  • Key ideas

  • Report Introduction

  • Executive summary of BRAF-mutated metastatic melanoma

  • Background and general description of the disease

  • Epidemiology and patient population

  • The United States

  • EU 5

  • Emerging treatments for BRAF-mutated metastatic melanoma

  • BRAF Mutant Metastatic Melanoma Market Outlook

  • Market Access and Reimbursement for Therapies

  • Appendix

  • BRAF Mutant Metastatic Melanoma Reporting Methodology

  • DelveInsight capabilities

  • Disclaimer

Click here to read more about BRAF Mutant Metastatic Melanoma Market

Media contact
Company Name: DelveInsight Business Research LLP
Contact person: aya kaul
Email: Send an e-mail
Telephone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
Condition: Snowfall
Country: USA
Website: https://www.delveinsight.com/

Leave a Comment